Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
Not yet recruiting · NCT07680088 · Registry updated 2026-07-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, anal squamous cell carcinoma, anus disorder, anus neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Not yet recruiting | Phase 2 | 2026-07-02 | NCT07680088 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| University of Texas Southwestern Medical Center | 295 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||